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.11.003INTRODUCTIONF or more than 30 years, the method for DNAsequencing devised by Frederick Sanger1 hasbeen used as the gold standard by which to
sequence the human genome (Fig 1), supporting the
Human Genome Project, published in 2001 at a cost of
US $3 billion ($1/nt).2 For more than the last 6 years,
technological improvements havemade the development
of novel techniques possible, offering scientific advan-
tages and at the same reducing costs. Thanks to Sanger’s
contribution (considered ‘‘first-generation’’ sequencing
technology), genomic research can now count on an
arsenal of cheaper, more straightforward, and less time-
consuming ‘‘second-’’ and ‘‘third-generation’’ technolo-
gies, known as next-generation sequencing (NGS). Their
primary goal is sequencing the whole genome of a1
Fig 1. Sanger sequencing. Schema representative of the technology and examples of wild-type DNA and sodium
bisulfite–converted DNA. Arrows in the sequence indicate the presence of methylated CpG sites. Abbreviations:
ddNTPs, Dideoxynucleotide triphosphates; ddATP, dideoxyadenosine triphosphate; ddCTP, dideoxycytidine
triphosphate; ddGTP, dideoxyguanosine triphosphate; ddTTP, dideoxythymidine triphosphate.
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2 Soto et al March 2016determined genetic source, enabling the detailed under-
standing of genomes, transcriptomes, and methylomes
and accelerating the acquisition of knowledge in biolog-
ical and biomedical research.
NGS development has facilitated the discovery of
new transcripts, the identification of polymorphisms
and their association with Mendelian and complex ge-
netic diseases, and a deeper analysis and understanding
of RNA structure, transcriptomes, and miRNomes. One
of the primary goals of clinical management is to find
new single-nucleotide variants and structural variants
so that they can be associated with phenotypical differ-
ences, achieving genomic personalized profiles with
medical purposes. As a first step, in 2004, the Interna-
tional Human Genome Sequencing Consortium pub-
lished the first and only finished-grade human
reference genome.3 Another example is the cancer
genome atlas (TCGA) database, a collaborative project
that catalogs genomic, transcriptomic, epigenomic, and
proteomic data for more than 30 tumor types—an excel-
lent source of data for the identification of robust prog-
nostic and predictive markers as well as therapeutic
targets. It is a practical in silico method to validate
research results in independent patient cohorts.
NGS embraced epigenetics quickly, with important
profits in recent years, thus promoting the knowledge
and positioning of epigenetics in science. Epigenetics
is the study of heritable gene regulation that does not
involve the DNA sequence. The 3 major types of epige-
netic regulators are DNA methylation by covalent
modification of cytosine-50, post-translational modifica-tions of histone tails, and microRNA (miRNA) gene
expression regulation.4 Their analysis is a key to under-
standing the heterogeneity and complexity of human
beings, whose various cell types express their genes in
hundreds of different ways (epigenome), despite having
an identical genome. In 1974, Riggs, Holliday, and Pugh
proposed cytosine DNAmethylation as a primary factor
in gene regulation and cellular proliferation5,6; nearly
50 years later, it remains the best-known epigenetic
event in human beings and the most frequent in human
cancer. DNA methylation analysis has become more
widely used, and thanks to NGS it is possible to under-
stand methylation status on a large scale and at a single-
base resolution. High sensitivity, specificity, and
scalability make NGS a powerful tool in the search
for new genetic and epigenetic biomarkers in clinical
cancer research, which is the theme of this study.NGS PLATFORMS AND TEMPLATES
NGS is focused on the implementation of specific
protocols regarding library template preparation,
sequencing, detection, alignment of the read, and subse-
quent data analysis by specialized software provided by
the various sequencing platforms. The need for robust
methods that produce a representative source of nucleic
acids from the genome under investigation should be of
particular interest. Current methods typically involve
randomly breaking genomic DNA (gDNA) into smaller
sizes, from which either fragment templates or mate-
pair templates are produced. A primary feature of
Translational Research
Volume 169 Soto et al 3NGS technologies is that the template is attached to a
solid surface or support immobilizing it. The immobili-
zation of spatially separated template sites allows thou-
sands to billions of simultaneous sequencing reactions.
Differences in protocols used by different platforms
create singularities; the first launched on the market
was Junior 454 FLX from Roche, which will be shut
down in 2016; the 2 technologies frequently used now
are the Illumina and Ion Torrent platforms (personalized
genome machine [PGM] and Proton) (Table I).
Illumina genome analyzer. With this platform, a
gDNA library can be created from any process that al-
lows a mixture of specific adaptor fragments up to
several base pairs (bp) in length. A particular feature
is the amplification step, known as ‘‘bridge’’ amplifica-
tion. Once the templates are obtained, Illumina uses
solid supports containing reverse and forward primers
that primewith specific adaptors linked to the templates,
so the amplicons remain immobilized during amplifica-
tion. Reaction sequencing is performed by synthesizing
the new strand using fluorescently labeled and chemi-
cally modified nucleotides, whereas the imaging step
follows each base incorporation step. The most repre-
sentative Illumina system is the HiSeq; however,
Illumina has launched 2 new systems, MiSeq and Next-
Seq500, whose special features promise to be available
in every laboratory soon. They share similar features in
terms of performance and hardware but differ in
throughput. MiSeq has been designed to analyze small
genomes, enabling up to 15 GB of output with 25 M
sequencing reads and 2 3 300 bp read lengths
(Table I). NextSeq500 is considered the first desktop
sequencer to enable analysis of the entire genome
(303 per run), exome, and transcriptome. This system
is characterized by its faster performance and easier
data analysis compared with its predecessors. It is a
moldable platform as it allows a low throughout
analysis, thus is an excellent alternative depending on
the objectives and needs of researchers. The latest
version of NextSeq500 provides improvements in
chemical synthesis for more accurate results.
Ion Torrent technology. On the basis of emulsion Poly-
merase Chain Reaction (PCR) library amplification, Ion
Torrent technology uses a novel method called semicon-
ductor sequencing. Generating libraries is the first step
in the workflow and consists of the Ion Torrent adapters
flanking the DNA fragments. Once the fragment li-
braries are prepared, they are clonally amplified by
emulsion PCR—a method of DNA amplification that
uses water in oil emulsion to isolate single DNA mole-
cules in aqueous microreactors. The sequencing reac-
tion is based on the detection of electric variation
generated by nucleotide insertion instead of light emis-
sion, resulting in higher speed, scalability, and low cost.In addition, there is no need for expensive and error-
prone modified bases, enzymatic cascades,
chemiluminescence, or fluorescence, which is an
advantage over Illumina. Life technologies offers 2
systems: the Ion PGM and the Ion Proton. Both differ
in run time and output; the PGM system has a
maximum output of 2 GB and a median performance
of 3 hours, whereas the Ion Proton system has up to
10 GB of output, ideal for exome sequencing.
PacBio technology. The technology that Pacific Bio-
sciences covers in terms of DNA sequencing is consid-
ered to be third generation, mainly because the
nucleotide sequence can be obtained in real time and
with a single molecule as a target source. This technol-
ogy, also known as single molecule real-time (SMRT)
sequencing, involves library elaboration with
subsequent sequencing, but without the need
whatsoever for amplification. The quantity of initial
gDNA is approximately 5 mg, which is mechanically
sheared, and the resulting fragments are fixed at the
ends so that specific adapters can be ligated,
generating library-size ranges from 250 bp to 20 kb.
This considerable range of base pairs is a unique
feature of PacBio technology, as it involves read
lengths from 10 kb and can reach 60 kb in length.
Errors tend to be random but not systematic, and less
coverage is required. The PacBio platform provides
complete and accurate views of all types of genomic
variation, revealing single-nucleotide variants,
structural variants, and epigenetics. The most
innovative element of this technology is the light
detection system, which comprises cells with
thousands of zero-mode waveguides (ZMWs). ZMWs
are nanophotonic structures that consist of a circular
hole, and they are considered to be the world’s
smallest light detection volume. A DNA template-
polymerase complex is immobilized at the bottom of
the ZMW and phospholinked nucleotides are
introduced into the ZMW chamber. The feature of the
ZMW enables the use of the high concentrations of
labeled nucleotides, which are necessary to support
rapid DNA sequencing by synthesis7 and confer the
improvements up to 1000-fold in reducing background
noise. Each of the 4 nucleotides is labeled with a
colored fluorophore and with every incorporation a
light pulse is produced. The base identification is
made according to the corresponding fluorescence of
the dye, thus allowing the sequencing of the DNA in
real time.NGS PLATFORMS IN EPIGENETICS
NGS technology has produced a complete revolution
in the genetic field; however, the most innovative
Table I. NSG platforms. Characteristics of the most representative NGS platforms and the associated list of methodologies for DNA methylation
characterization
Next-generation sequencing platforms
Roche: 454 (GS FLX) Illumina: Solexa Ion Torrent PacBio
Amplification
Emulsion PCR (emPCR) Bridge PCR emPCR None
Sequencing
Pyrosequencing Sequencing by synthesis Semiconductor sequencing Single molecule real-time sequencing
Read length
650 bp 2 3 150 and 2 3 300 (only Miseq) 400 bp .3000 bp
Particular features
Pros: long reads, short run time, de novo
genome, and transcriptome assembly
Cons: high cost, homopolymer errors,
support of platform ending 2016
Pros: high throughput, straightforward
performance. The most used platform
Cons: short reads
Pros: ultra high throughput
Cons: short reads, higher error rate than
Illumina, more hands-on time
Pros: ultra high throughput, longest read in
industry
Cons: high error rate
Strengths
454 GS Jr: lower cost per run than 454
FLX1
MiSeq: moderate-cost instrument and
runs; low cost per megabyte for a small
platform; fastest Illumina run times and
longest Illumina read lengths
Ion Torrent—PGM: moderately low-cost
instrument for high throughput
applications; similar cost to MiSeq, but
PII and PIII chips will give more reads
than MiSeq
Single molecule real-time sequencing;
longest available read length; ability to
detect base modifications; short
instrument run time; random error
profile; modest cost per sample; many
methods being developed
454 FLX1: longest available contiguous
reads on any second generation
instrument (ie, nonsingle-molecule
instrument)
NextSeq500: easy to use; moderate
instrument and run costs; new
chemistry and flow cells with lots of
room to grow
Ion Torrent—Proton: moderately low-cost
instrument for high throughput
applications; similar cost to MiSeq, but
PII and PIII chips will give more reads
than MiSeq
SOLiD—5500/5500xl/5500W: Each
lane of flow-chip can be run
independently; high accuracy; output in
bases (not color-space); ability to rescue
failed sequencing cycles; 96 validated
barcodes per lane; throughput of 20–
30 Gb/d
Illumina HiSeq 2500: low cost per
megabyte of data; can run high output (8
lane) and rapid run (2 lane) flow cells with
several possible read-length
configurations
Limitations
454 GS Jr: high cost per megabyte; few
reads; shorter reads than FLX1; similar
instrument cost to MiSeq and PGM;
support of platform ending in mid-2016
MiSeq: relatively few reads and higher cost
per megabyte compared with HiSeq
Ion Torrent—PGM: higher error rate, more
hands-on time, and fewer overall bases
of data than Illumina; higher cost per
megabyte of data than most Illumina
instruments; smaller user community
High error rates; low total number of reads
per run; high cost per megabyte; high
capital cost; many methods still in
development; weak company
performance; cost prohibitive and
insufficient accuracy
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Volume 169 Soto et al 5application of NGS is in the field of epigenetics. NGS
has contributed to increased knowledge of differentially
methylated DNA regions and to the discovery of new
gene regulatory elements involved in the epigenetic ma-
chinery. Most importantly, NGS represents a significant
tool to achieve characterizations of the DNA methyl-
ome, helping increase in understanding of specific
cell-type expression patterns that cannot be explained
at the genetic level and illuminating the relationships
between DNA methylation patterns and subsets of the
transcriptome. NGS allows analysis of the entire
genome so that methylome can be characterized at sin-
gle base-pair resolution. Because the methylation signa-
ture is not preserved in PCR amplification, various
approaches have been developed to conserve the epige-
netic landmark in the DNA. These pretreatments are pri-
marily endonuclease digestion, affinity enrichment, and
bisulfite conversion; their combination with analytical
methodologies results in a variety of techniques for
DNA methylation analysis that are described as follows
(Table II).
Methodologies without DNA conversion. These ap-
proaches always involve a partial analysis of the entire
methylome and are based on endonuclease digestion
and affinity enrichment procedures.
Restriction endonuclease method—cutting the methyl-
ated DNA. The most frequent restriction endonucleases
used in methylation studies are HpaII and MspI. These
enzymes have other representation states known as
isoschizomers, which recognize the cleavage site
50-CCGG-30.8 MspI digests at the site regardless of
methylation status, whereasHpaII digests only at unme-
thylated sites9; such capability has been adapted to
perform methylation analysis throughout the entire
genome using less input DNA. Methyl-Seq methodol-
ogy combines restriction enzymes with NGS generating
libraries constructed from patterns created by these iso-
schizomers. Fragments are ligated with next-generation
adapters and are size selected for sequencing. This
library can yield millions of short sequence tags that
are 25–35 bp in length (3 3 106 tags per HpaII library
and 1 3 107 tags per MspI library),9 covering more
than 90,000 regions in the methylation analysis. Its
primary advantages are reproducibility, relatively easy
performance, sensitivity, and low cost. Limitations
include reliance of the analysis on a specific subset of
HpaII restriction enzyme cleavage sites, which appear
within 35–75 bp of each other in the human genome.
This significantly limits the number of CpG dinucleo-
tides assayed, but nevertheless provides a preview of
regional methylation patterns.
Enrichingmethylated DNA: Methyl Cap-seq andMeDIP-
seq. Because of the 28 million CpGs present in the hu-
man genome, of which 70%–80% are methylated,10,11
Table II. Technologies formethylomeassessment. Comparison of the key characteristics for the principalmethodologies used to approachglobal DNA
methylation
Key characteristics WGBS MeDIP-seq Methyl Cap-seq RRBS SureSelect Methyl-seq SMRT-seq
Human methylation
450K
Resolution Single base 150 bp 150 bp Single base Single base Single base Single base
Reads per sample .500 million reads 50 million reads 30 million reads 10 million reads 50 million reads Microarray
SNP detection Yes Yes Yes Yes Yes Yes No
Enrichment No Yes Yes Yes Yes No No
Regions covered .28 million CpGs 23 million CpGs 23 million CpGs 2 million CpGs (85%
of CpG islands and
60% of promoters)
3.7 million CpGs
(islands, shores and
shelves, DNAse I
hypersensitive sites,
Refseq genes,
Ensembl regulatory
features)
.28 million CpGs 485,000 CpGs (96%
CpG islands, shore
and shelves, 99%
RefSeq promoters,
non-CpG
methylated sites,
and miRNA
promoters)
Regions not
covered
— Genome-wide CpGs
and non-CpG
methylation
Areas with less dense
5-mC are missed
Genome-wide CpGs
and non-CpG
methylation
Areas with less dense
5-mC are missed
CpGs in areas without
the enzyme
restriction site
Regions without
covered probes
— Regions outside the
platform
Pros CpGs in dense, less
dense, and repeat
regions are covered
Sonication
fragmentation
avoids bias toward
targeting specific
sites
Antibody-based
selection is
independent of
sequence and does
not enrich for 5hmC
because of antibody
specificity
More sensitive than
Methyl-Cap in
regions of low CpG
density
Methyl-binding domain
proteins do not
interact with 5hmC
Methyl-binding domain
is more sensitive
than MeDIP in
regions with higher
CpG density such
as CpG islands
High sensitivity without
high cost by only
sequencing a
reduced,
representative
sample of the whole
genome
Probes are designed
based on the
primary DNA
sequence and are
not limited to
regions of high or
low CpG density or
affected by the
inherent methylation
state of the sample
Sonication
fragmentation
avoids bias toward
targeting specific
sites
Its light detection
technology allows
us to reduce
background noise
by up to 1000-fold
It is less consuming
time (20 h)
It is suitable for
coupling with
bisulfite conversion
Its methodology of
sequencing allows
us to assess
hydroxy and methyl
cytokines
simultaneously
The most widely used
and standardized
data analysis
Cons Bisulfite conversion
does not distinguish
between 5-mC and
5hmC. High DNA
input
Antibody-based
selection is biased
toward
hypermethylated
regions
Protein-based
selection is biased
toward
hypermethylated
regions
Restriction enzymes
cut at specific sites,
providing biased
sequence selection
(CpG density)
Analyze target
candidate regions,
not the whole
genome
High DNA input
High error rate
Bias based on affinity
of polymerase for
methylated
cytokines
Probes are
methylation-state
dependent, and
only for human
Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; RRBS, reduced representation bisulfite sequencing; SMRT, single molecule real time; WGBS, whole-genome bisulfite
sequencing.
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Volume 169 Soto et al 7advances are needed in the assessment of highly
condensed CpG areas; assessment is now possible,
thanks to enrichment techniques. There are various
affinity-based methodologies that can be coupled to
NGS; however, they do not yield information on indi-
vidual CpG dinucleotides and require substantial exper-
imental and bioinformatics adjustments for varying
CpG density at different regions of the genome
(Table II).
Methyl Cap-seq is a procedure based on the capture of
methylated DNA using the methyl-binding domain of
methyl CpG binding protein 2 and subsequent NGS of
eluted DNA. The affinity of the methylated DNA–
methyl-binding domain interaction allows the DNA to
be separated by salt gradients according to its CpG
methylation density. This feature stratifies the genome
from regions with low or no methyl CpG dinucleo-
tides—in low salt elution—to highly methylated re-
gions, obtaining less complex areas and thus a deep
sequence coverage.
MeDIP-seq is also an affinity enrichment tool, which
combines DNA immunoprecipitation by anti–5-
methylcytosine (anti-5-mC) antibodies with massive
sequencing of areas with high and low methylation
levels (Methylated DNA immunoprecipitation). The
performance of MeDIP initiates sonication of gDNA,
obtaining 300–1000 bp fragments followed by subse-
quent denaturalization, which is crucial for obtaining
an efficient antibody binding.12 Fragment size plays a
main role in downstream steps: short fragments mean
higher resolution; however, antibodies need several
binding sites.13 After enrichment treatment, the DNA
is purified for antibody removal and for sequencing by
any of the platforms described. MeDIP-seq was the
tool used to obtain the first high-resolution whole-
genome DNA methylation profile in mammals14; how-
ever, it displays a bias toward highly methylated re-
gions, missing a significant proportion of the genome.15
Methodologies based on bisulfite-converted
DNA. DNA sodium bisulfite treatment introduces chem-
ical modifications to discriminate between methylated
and nonmethylated cytosines in a CpG context. This
eliminates the bias toward repetitive and CpG-rich
sequences that are introduced by the previously noted
methodologies. Bisulfite treatment transforms an
epigenetic into a genetic difference because the
unmethylated cytosines are deaminated to uracil more
rapidly than the methylated cytosines, maintaining the
methylation landmark at single-base resolution during
PCR amplifications.16,17 There are various established
techniques for conjugating converted DNA, including
Sanger sequencing (bisulfite sequencing [BS]),
methylation-specific PCR (MSP), MethyLight
(quantitative MSP [qMSP]), arrays (Golden Gate fromIllumina), and NGS techniques that offer a whole-
genome methylation analysis (methylome).
Partial sequencing of bisulfite-modified DNA: reduced
representation bisulfite sequencing and SureSelect.
Reduced representation bisulfite sequencing (RRBS) is
a DNAwide methylation analysis technique considered
as a combination of enrichment and modifying tech-
niques.18 First, it encompasses random DNA fragmen-
tation over 30-CCGG-50 sequences by MspI. This step
is biased in areas with low CpG content, although it
grants single-base resolution as complete as the analysis
of the whole-genome bisulfite sequencing (WGBS),
described subsequently. After the end repair, A-tailing,
and ligation with methylated adapters, the DNA frag-
ments from 50 to 250 bp are purified by gel electropho-
resis. These are representative of most promoter length
and CpG islands. Next, the modified DNA is amplified
and sequenced. This reduced representation implies a
lower number of reads necessary to yield an accurate
sequencing, involving less cost and time compared
with WGBS. Various companies have launched plat-
forms based on RRBS methodology with improved ver-
sions (Methyl-MiniSeq/Methyl-MidiSeq) able to detect
from 3–4 to 8–9 M unique CpG sites, capturing more
than 85% of all CpG islands and more than 80% of
gene promoters (Table II).
SureSelect Methyl-Seq is a new system developed by
Agilent to enrich and sequence desired regions in the
genome regardless of the methylation state or the CpG
content of such areas. This platform assesses CpG
islands, gene promoters, DNase I hypersensitive sites,
and RefSeq genes. It also covers regulatory features
and known tissue- and tumor-specific differentially
methylated regions (DMRs) and CPG island shores and
shelves. CpG island shores are 2 kb away from islands
and CpG island shelves are 4 kb away. Their study is
important because methylation status is related to gene
expression inhibition.19 The protocol is based on bio-
tinylated RNA probes to capture target epigenomic re-
gions and only requires 2–3 mg of gDNA for library
construction. The gDNA is randomly fragmented to
mean sizes of approximately 250 bp, then fragments
are ‘‘fixed,’’ creating blunt ends and adding dA in the
3’ ends so the methylated modified adapters bind to these
fragments. The libraries are then hybridized with bio-
tinylated RNA, andmagnetic beads covered with strepta-
vidin are used for target fragment separation. The
selected fragments are bisulfite-treated, PCR-amplified,
and sequenced by an NGS platform. SureSelect investi-
gates areas undetected by RRBS or MeDIP.
Global analysis of DNA methylation. The enrichment
approaches described previously offer clear cost benefits
for analysis of many samples and large genomes, but risk
missing DNAmethylation occurring outside the captured
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achieved using WGBS. This methodology assesses the
methylation state along the entire genome, yielding
quantitative, qualitative, and positional results in a
single-nucleotide resolution. InWGBS, the gDNA is pre-
viously randomly fragmented and its ends fixed so the
methylated sequence adapters can be ligated. Such
adapters have all cytosines replaced with 5’-mCs to pre-
vent their deamination in the bisulfite conversion reac-
tion. After ligation, the products are purified and
selected by gel size (275–350 bp), bisulfite-modified,
amplified, and subject tomassive parallel sequencing, us-
ing any of the platforms described previously.
The current read length ranges from 400 to 600 bp
(Table I), which is important in DNA methylation anal-
ysis; the more coverage, the more CpG sites are
analyzed, thus determining complex methylation pat-
terns of individual DNA molecules. Longer reads are
more accurately aligned to the reference sequence,
particularly in repetitive regions of the genome,
covering more genotype information such as Single
Nucleotide Polymorphisms, making it possible to
analyze the correlation between DNA methylation and
genotype.20,21 Illumina is the technology of choice for
DNAmethylation analysis, both at a genome-wide level
and in targeted regions, and has contributed to the devel-
opment of the first single-base resolution-wide DNA
methylome profile.
Dual methodology with or without DNA
conversion. PacBio technology is considered to be the
ultimate approach in massive sequencing, thanks to
ZMW technology, the capacity of sequencing 1 single
molecule in real time and in addition the lack of need
for amplification, conferring an advantage in terms of
time consumed compared with other platforms. As
stated earlier, DNA methylation status can be assessed
through techniques that involve chemical modification
of the DNA. SMRT confers duality in this regard
because it can be performed with or without DNA bisul-
fite treatment. The canonical SMRT sequencing for
methylation analysis does not involve amplification
steps, therefore the methyl fingerprints are conserved.
PacBio technology sequencing can identify methylation
modifications of nucleotides such as N6-
methyladenosine, 5-hydroxymethyl cytosines, and 5-
mCs.7 Metrics obtained through the dynamics of
fluorescence pulses during sequencing are essential
for identifying the DNA polymerase kinetics. Such
data are based on emission spectra, the duration of the
pulse, and the interval between successive pulses. The
presence of methylated bases affects polymerase
kinetics during SMRT sequencing, allowing the
identification of modified nucleotides.7 Because there
is no need for sample preparation, through thisapproach it is possible to assess the methylation and
hydroxymethylation states at the same time and in a
single base-pair resolution. SMRT also can be
performed with DNA bisulfite modification to
construct a method for quantitative and multiplex-
targeted BS with long reads. This type of coupling can
assess methylation status across 1.5 kb regions,
interrogating 91% of the CpGs.22 This combination
confers advantages over other lower-throughput
quantitative CpG methylation methods, and it could
be suitable for diagnostic panels in cancer research.METHYLATION ARRAYS
Before the advent of WGBS, the methylation array
approach to massive DNA methylation analysis was
developed by Illumina to reveal the methylation state
at a single-base resolution. It is based on bisulfite con-
version assessing specific CpG dinucleotides by
customized probes. Although this approach is not
appropriate for massive analysis techniques, it has
been used since 2008 to assess DNA methylation
(Fig 2) in many translational analyses and has been
used in databases such as TCGA. It was originally rep-
resented by the 27K and the Golden Gate assays, but
currently the most widely used is the Infinium Human-
Methylation450 BeadChip Kit (450K), encompassing
nearly 90% of the 27K probes. This microarray contains
probes for assessing approximately 485,000 CpG sites,
covering 96% of CpG islands, 99% of RefSeq genes,
and 50 and 30 untranslated region gene body and shore
and shelf regions. The 450K technology is a mixture
of 2 chemistries, Infinium I, and Infinium II. The Infin-
ium I assay was implemented on 27K using 2 types of
beads (U/M), each with probes targeting a specific un-
methylated or methylated locus. An unmethylated
bead cannot hybridize with a methylated locus and
vice versa because of a mismatch between bases. Fluo-
rescence detection is conducted in 2 channels with the
same color. The Infinium II assay requires just 1 bead
with a single class of probe, thus detecting both alleles.
In this case, fluorescence is detected in the same channel
with 2 colors: methylated (green) and unmethylated
(red). In both assays, the percentage of methylation is
calculated in the form of a b-value corresponding to
the ratio of the methylated signal over the sum of the
methylated and unmethylated signals, or in the form
of an M-value as the log2 ratio of the intensities of the
methylated probe vs the unmethylated probe.23 This
combination of chemistries enables 450K enlarged
CpG coverage, but also might induce bias regarding am-
biguity between the 2 assays in terms of the number of
CpGs and the CpGs identified as methylated. There is
also divergence reflected in the b-values from these
Fig 2. Overview of evaluated methylomes. Representation of the methylomes produced by NGS sequencing
(WGBS, Methyl Cap-seq, MeDIP-seq, and RRBS) vs those produced by the methylation array 450K from
2011 to July 2015. Data extracted from GEO. NGS, next-generation sequencing; RRBS, reduced representation
bisulfite sequencing; WGBS, whole-genome bisulfite sequencing.
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are less certain because reproducibility is more difficult
to achieve.24 These findings can be overcome with an
appropriate bioinformatics analysis, using strategies of
correction and normalization. Infinium II designs are
applied whenever possible; however, in those positions
where designs are not achievable, the use of Infinium I
could introduce some methylation status predisposition
because the design of these probes is based on the pre-
sumption that 90% of the nearby 50 bp contains CpG
sites with the same methylation profile as the target po-
sition.
Despite these particularities, 450K assays are consid-
ered an accurate and robust technology for the analysis
of low CpG density areas. In addition, several samples
can be analyzed simultaneously, requiring less input
of gDNA. Its protocols are relatively easy to perform,
and the running cost is much lower than WGBS. For
any epigenetic project, particularly those involving clin-
ical research, a powerful approach could be the combi-
nation of WGBS and 450K as discovery and screening
tools, respectively.
TRANSLATIONAL APPLICATIONS OF METHYLOME
STUDIES IN CANCER
Although the use of NGS in methylome studies has
increased in the last 2 years, most translational cancer
studies are still being developed using the HumanMe-
thylation450K platform (96%), primarily because of
the price-quality relationship. In fact, by the end of
July 2015, use of the 450K platform has almost reached
as many determinations as those reported during all2014, with 12 times greater determinations than those
reached by the NGS platform RRBS (Fig 2).
It is interesting to note that complementary to human
methylation arrays, many studies have combined
expression arrays and epigenetic reactivation treatments
with demethylating and histone deacetylase (HDAC)
enzymes for global methylation profile screenings.
This approach has identified novel potential candidate
genes and miRNAs under epigenetic regulation in
many tumors such as colorectal, renal, and prostate,25,26
as well as the identification of predictive markers under
epigenetic regulation, as has been reported for insulin-
like growth factor binding protein 3 (IGFBP-3) in
non-small cell lung cancer (NSCLC).27 This approach
has the advantage of identifying changes at the
messenger RNA level, directly validating whether the
presence of hypermethylated positions are involved in
gene expression changes, whereas the human methyl-
ation array only points to the presence or absence of
DMRs at the DNA level. This is the primary reason
many recent studies combine DNA methylation (using
450K arrays) with RNA expression profiles (using
transcriptome-NGS techniques), obtaining a more
global view regarding epigenetic regulation in cancer.
Here, we present some examples of approaches to study
the DNA methylation profile in some of the most rele-
vant tumor types.
One of the primary motivations for achieving a
methylation analysis of clinical samples is the addi-
tional information that can be obtained on pharmacoepi-
genomics; in fact, the presence of methylation at
specific candidates in certain tumor types is related to
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NGS for this purpose is also of great importance in
the clinical epigenetics field.
Pharmacoepigenomics. Epigenetic treatment is a new
field that includes DNA demethylation and histone
modification as targets, in the effort to re-establish
epigenetic balance. Successful target identification
associated with feasible epigenetic treatment could
lead to improvements in cancer therapies. The first
description of the effects of azanucleoside drugs
(DNA methyltransferase [DNMT] inhibitors) on the
differentiated state of cells dates back 30 years.28
These compounds are analogous cytokines that
intercalate into DNA, blocking the DNA
methyltransferase function. It took almost 4 decades
for the US Food and Drug Administration (FDA) to
approve the use of this drug for treatment of
myelodysplastic syndromes,29 and currently, it is also
used for acute myeloid leukemia (AML).30 Another
element that plays a role in pharmacoepigenomics is
related to a histone biochemical modification known
as acetylation. Histone acetylation signals a
transcriptional state contributing to gene expression,
and conversely, histone deacetylation induces a
repression state. On the basis of this scenario, there
are HDAC inhibitors that when conjugated with
DNMT inhibitors comprise epigenetic treatments.
HDAC inhibitors have been used for the treatment of
cutaneous T-cell lymphoma in patients with
progressive, persistent, or recurrent disease.31 It has
been demonstrated that certain solid tumors respond
to DNMT and HDAC inhibitor treatments, but
significant clinical outcomes are obtained with
hematologic malignancies.32 Such treatments are
unspecific, because they focus on global epigenetic
alterations displayed in tumors. Until 2013, only 5
epigenetic drugs had been approved by the FDA: 2
DNMT inhibitors, 2 HDAC inhibitors, and a Janus
Kinase1/2 inhibitor. This last drug is a tyrosine kinase
inhibitor that has been shown to have a clear role in
chromatin signaling, and it is used for treatment of
intermediate- or high-risk myelofibrosis. In March
2015, the FDA approved a new epigenetic-targeted
therapeutic called panobinostat (HDAC inhibitor) for
treating multiple myeloma (MM). This treatment
doubles the time of disease progression compared
with those receiving placebo. The key question for
those epigenetic reactivation treatments is how to
increase their specificity to be able to achieve
personalized medicine. A new generation of targeted
epigenetic drugs is now possible, thanks to increased
resolution of genomic and epigenetic profiling
methods. Therefore, targeted epigenetic treatments,such as the specific inhibition of enzymes by small
molecules can be developed. For example, the
interaction between histones and proteins can be used
for this purpose. Histone acetylation regulates gene
expression indirectly through the action of the so-
called bromodomain and extraterminal proteins that
recognize and bind to acetylated lysine residues and
follow activate transcription factors. The inhibition of
these molecules leads to a direct regulation of
transcription.33 In another specific case, concerning
mixed lineage leukemia (MLL), gene translocations
generated in this malignancy foster recruitment of
DOT1L, which is a histone methyltransferase in
histone H3 lysine 79 (H3K79) and is considered as a
possible inductor of leukogenesis. Daigle et al34 has
developed a compound called EPZ004777, which
specifically inhibits this methyltransferase, leading to
deadly effects on treated leukemia cells harboring
MLL translocations and also leading to increased
survival in xenograft models. Despite low coverage of
these treatments in some types of cancer, clinical trials
are being developed with the aim of discovering new
cancer treatment profiles based on their combination
with epigenetics and conventional treatment. For
instance, a phase I clinical trial involving decitabine
(DNMT inhibitor) and interleukin 2 in melanoma has
shown an improved response in 31% of these patients.35
Another significant and attractive aspect of pharma-
coepigenomics is the synergist effect that can be
achieved in antitumor treatments. Hypermethylation
patterns of particular genes can predict the response to
specific treatments: O6-methylguanine-DNA methyl-
transferase (MGMT) has been found to be hypermethy-
lated in gliomas, thus becoming a predictor of the
response to alkylating agents such as temozolomide.36
The defective expression of this gene impairs reparation
of damage caused by the drug. The breast cancer 1
(BRCA1) gene is frequently mutated in inherited breast
cancer and transcriptional repression related to hyper-
methylation is also observed in breast and ovarian can-
cers.37 Patients who harbor BRCA1 genetic and
epigenetic aberrations benefit in terms of conventional
chemotherapy or Poly (ADP-ribose) polymerase
(PARP) inhibitor-targeted treatment (proteins related
to base excision repair).38 Hypermethylation of human
mutL homolog-1 (hMLH1) is another gene implicated
in the DNA repair system, specifically MMR (mismatch
repair). A loss of MMR has been related to anticancer
drug resistance in vitro,39 and a lack of expression of
hMLH1 in ovarian cancer is related to promoter hyper-
methylation.40 Epigenetic treatment of cisplatin-
resistant ovarian cancer cell lines results in drug sensiti-
zation.41 Similarly, in NSCLC, hypermethylation of the
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tance. In addition, cell reactivation treatment with
DNMT and HDAC inhibitors recovers the initial sensi-
tivity.27
It is hoped that in the near future, multiple epigenetic
drugs could be implemented that individually affect
gene expression and at the same time have a synergist
effect with conventional therapies including chemo-
therapy and radiotherapy, decreasing in that way the un-
desired secondary effects.
Clinical epigenetic test. The detection of epigenetic al-
terations is a promising tool for the diagnosis and prog-
nosis of disease and for the prediction of treatment
response. As stated earlier, the best example of a methyl-
ation marker in clinical use is MGMT hypermethylation
in glioma patients. The hypermethylation of the MGMT
gene has been reported in multiple cancers including gli-
omas and colorectal carcinoma.36,42,43 The 2013
National Comprehensive Cancer Network Guidelines
recommend the use of temozolomide as adjuvant
therapy in patients with MGMT gene methylation. The
indication for this analysis includes all patients with
glioblastoma for whom stratification for treatment is
needed, and the specimen requirement is only the DNA
obtained from the formalin-fixed paraffin-embedded
tissue blocks. For prostate cancer diagnoses and
prognoses, the most promising epibiomarker candidate
is DNA methylation at the glutathione S-transferase pi
1 (GSTP1) gene. This gene codifies an enzyme
involved in cellular detoxification and is mainly
repressed in prostate cancer.44,45 More than 30
independent studies confirm an increase in DNA
methylation in this tumor type, validating its use as a
biomarker of prostate cancer with high sensitivity
(82%) and specificity (95%).46,47 Hypermethylation of
GSTP1 is considered an early tumorigenesis event,
with significance as a diagnostic biomarker.
Another candidate reported mainly in sporadic colo-
rectal cancer (CRC) is the biallelic hMLH1. In fact,
this event together with B-Raf Proto-Oncogene muta-
tion, in patients with a lack of family history of cancer,
helps to distinguish sporadic microsatellite instability
CRC from Lynch syndrome patients. The presence of
a CpG island methylator phenotype has been reported
that is based on 8 markers including hMLH1 in colo-
rectal cancer, but the CpG island methylator pheno-
type–associated DNA hypermethylation of hMLH1
seems to be the dominant mechanism for the develop-
ment of sporadic CRC with microsatellite instability.48
In addition, a global approach to study the DNAmethyl-
ation profile of normal and CRC samples might
contribute to increasing the accuracy of the CRC classi-
fication.49 These commercial tests are available for lab-oratory and clinical trial use, although their clinical
application for diagnosis is achieving the authorities’
approval. The commercial kit for detecting methylation
at IGFBP-3 gene is under development, and its use is
directed toward the identification of NSCLC patients
who could benefit more from concomitant chemo-
therapy-radiotherapy.27,50,51
Lung cancer. Lung cancer is the worldwide leader in
tumor-related deaths. Various approaches have been
attempted to increase understanding of the molecular
events responsible for its initiation and progression. A
study encompassing a genetic and epigenetic scan of
26 lung adenocarcinoma cell lines by Whole Genome
Sequencing and BS established connections between
the genome and epigenome, finding a large number of
mutations encompassing promoters and epigenetic-
related enhancers. These findings were crossed with
previous studies searching for cancer signatures,52,53
and the CDKN2A gene emerged as a candidate,
presenting deletions in 13 of 26 cancer cell lines.
Methylation at the promoters, analyzed by SureSelect,
was different between cell lines and few promoters
presented a hypermethylated status. CDKN2A was
found hypermethylated in 6 cell lines,54 which has
been reported in several malignancies55; it is
hypermethylated in 67% of adenocarcinomas and 70%
of squamous lung cancer samples.56 In addition, the
epigenetic inactivation of CDKN2A could be
considered an early event because a direct relation has
been observed between the gradual emergence of
histopathologic changes and its increasing
hypermethylation in lung cancer.57 Other evidence
showing p16 methylation as an early event in lung
cancer was described in a study finding
hypermethylation of CDKN2A in 18% of the biopsies
belonging to patients with lung cancer, whereas no
methylation was observed in cancer-free individuals.58
The integration of mutations and silencing of
CDKN2A could increase the identification of tumor
cells carrying more aggressive characteristics and
might be biomarkers for early detection in lung cancer.
Another study assessing DNA methylation by 450K
and gene expression arrays in cancer cell lines showed
2 biological subsets of lung cancer. The DMR’s reflected
methylation signatures that were clustered into 2 sub-
types: epithelial-like and mesenchymal-like tumors.59
The hypermethylated areas corresponded with gene pro-
moterswith decreased expression, which was restored af-
ter epigenetic reactivation treatment. The mesenchymal-
like tumors exhibited greater hypermethylated levels
compared with the epithelial, and there was specific pro-
moter hypomethylation at the ERBB2 gene; in addition,
they were more sensitive to DNA damaging agents,
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nib.59 These findings are relevant for choosing a therapy
for these patients regarding the differential response to
erlotinib in patients with overexpression or mutation on
ERBB2.59,60 This molecular classification based on
methylation profiles contributes to personalized
medicine, helping increase in success rates, and
reducing adverse effects in nonresponders.
Ovarian cancer. NGS technologies can also be used in
the monitoring of antitumoral therapies, evaluating the
possible role of methylation over tumor suppressor genes
that could confer platinum resistance. One of the tumor
types with higher rates of chemotherapy resistance is
ovarian cancer. An in vitro assay performed with
Methyl-Cap-seq on matched sensitive (A2780) and
cisplatin-resistant (A2780CP) ovarian cancer cell lines
searched for DMRs. Firstly, it validated the
methylation dogma in cancer as lower global
methylation was found in the resistant cell line
compared with its counterpart,61 and almost 50% of the
methylated positions were located at areas within 5 kb
of transcription start sites. An ontology analysis
showed that hypermethylated genes in A2870 cells
were enriched in antiapoptosis and negative regulation
of cell death,61 which could confer cisplatin sensitivity
to these cells. The search for biomarkers for ovarian
cancer is also centered on early diagnosis, which has
not improved in recent years. A retrospective study
sought to find methylation differences between healthy
individuals and patients with ovarian cancer based on
lymphocyte methylation signatures previously
described in case and control approaches.62,63 This
search was conducted by methylation 27K and 450K
arrays yielding a low quantity of statistically significant
risk-indicative probes between groups. There was a
specific methylation trend in patients showing an area
close to Dual Specificity Phosphatase 13 (DUSP13) as
the most densely methylated.64 Indirect participation of
DUSP13 on NSCLC progression is because of
epigenetic repression by the histone demethylase
Lysine (K)-Specific Demethylase 2A. Its role in
promoting lung tumorigenesis is associated with the
decrease in dephosphorylation of Extracellular Signal-
Related Kinase1/2, promoting enhanced Extracellular
Signal-Related Kinase1/2 signaling. Considering these
data in lung cancer, the role of epigenetic regulation of
DUSP13 in ovarian cancer should be further
investigated to reveal whether this event could act as a
potential marker for early diagnosis of this malignancy.
Unfortunately, there were no significant CpG sites
related to overall survival between groups; however,
these findings could serve as platforms for future
studies based on WGBS.Breast cancer. Breast cancer is one of the most prev-
alent malignancies in women, and a complete coverage
of DNA methylation status could yield useful informa-
tion on the biology of the disease. In the context of
WGBS, Lin et al developed a massive analysis of
methylation in normal breast tissue, fibroadenoma,
invasive ductal carcinomas, and the cancer cell line
(MCF7). The data showed a lower genome-wide
methylation in cancer cell lines compared with normal
cells and primary tumors. Conversely, and as
expected, the methylation analysis in genomic
locations showed more methylation of CpG islands in
the promoter regions in cancer cell lines than in
normal cells and fibroadenomas.65 Along with WGBS,
RNA-seq was performed to correlate gene expression
with methylation, and it surprisingly found that 5
genes showing strong methylation were highly
expressed. Four were the noncoding RNAs U1,
SCARNA7, SCARNA9L, and SNORD71, and 1 was the
coding gene PPP2R2D.65 In this case, DNA
methylation is not the regulatory element for such
genes; however, methylation analysis of MCF7 cells
and the ductal carcinoma cells HCC1954 showed an
unusual hypomethylation of several promoters on the
X chromosome, including AR, HMGB3, and LAGE3.
Such hypomethylation was correlated with decreased
free relapse and survival rates, pointing which
indicated that failure in the maintenance of promoter
methylation in this chromosome could serve as
another area of study in breast cancer.
Hematologic malignancies. Multiple myeloma. A high
throughput methylation screening was also conducted
for this pathology. The techniques combined were as
follows: first, the 450K array in both normal andMM tu-
mor cell lines was used to assess general epigenetic fea-
tures. Second, WGBS was conducted on those cells
showing extremely hypermethylation or hypomethyla-
tion signatures. The analysis showed a DMR profile
ranking from hypermethylated to hypomethylated
MM cell lines compared with normal cells, and such
heterogeneity was located in specific genomic regions.
MM hypermethylated sites were located in regions lack-
ing CpG islands, and interestingly, most hypermethy-
lated CpGs were located within enhancer regions.66
These findings contrast with others obtained for cancer
in which the hypermethylated CpG sites correspond to a
CpG island, specifically, within promoters.67 To reveal a
functional consequence of this enhancer methylation,
RNA-seq was performed in the enhancer-related genes,
finding approximately 50 genes showing a strong in-
verse correlation between expression and enhancer
methylation.66 The ontology analysis performed on
these genes was enriched in terms associated with
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DNA methylation as a regulator of transcriptional pro-
cesses in a nonpromoter methylation manner, but con-
trolling regulatory elements such as enhancers whose
methylation appears to have consequences in B-cell
maturation, thus reacquiring stem cell features.
Acute myeloid leukemia. Leukemias are cancers that
originate in cells that normally develop into various
types of blood cells. AML is known also as acute myelo-
cytic leukemia, acute myelogenous leukemia, acute
granulocytic leukemia, and acute nonlymphocytic leu-
kemia. It encompasses a spectrum of several somatic
mutations and chromosomal translocations. The term
‘‘acute’’ means that this disease can progress rapidly
and, if not treated, is likely fatal in a few months. The
term ‘‘myeloid’’ refers to the type of cell from which
the leukemia originates. As has been shown in other tu-
mor types, the genetic background alone is not enough
to explain the behavior and origins of these types of pa-
thologies, but it goes hand in hand with the epigenetic
landscape. The same scenario occurs in AML, where
combined analyses of these fields yield a subclassifi-
cation of this malignancy based on the genetic and
epigenetic profiles exposed. For example, a specific
translocation involving chromosome 11q23 generates
a protein fusion pattern in AML known as MML. This
fusion has transcriptional consequences favoring leuko-
genesis. Similarly, heterozygous somatic mutations of
isocitrate dehydrogenase 1or 2 (IDH1 or 2) result in
an increase in enzymatic activity because of an accumu-
lation of the substrate 2KG, which in turn acts as an in-
hibitor of Tet methylcytosine dioxygenase proteins.68
To determine the epigenetic influence on these subtypes
of AML, Alkalin et al conducted a study on 2 IDHmut
AML samples: 2 MLL cases and 2 normal bone marrow
samples, seeking to analyze CpGmethylation status in a
broader manner than conventional RRBS can confer.
For this purpose, modifications in RRBS protocol
reduced sample loss in creating libraries and enlarged
coverage of CpG promoters and also other regions.
This new approach was called enhanced RRBS.68 The
analyses yielded a high grade of correlation in methyl-
ation intrasamples but not intersamples, which means
that the genetic background also correlates with the
epigenetic landscape and suggests that methylation is
systematic rather than random. In addition, this clus-
tering is also congruent with the nature of methylation,
thus the IDHmut samples exhibited CpGs hypermethy-
lation in almost all chromosomes, whereas CpGs were
predominantly hypomethylated in MLL. To complete
this characterization, it was found through enrichment
analyses that every subtype of AML also displayed
divergent pathways. For example, in IDHmut samples,
differentially methylated cytokines were enriched incadherine, Notch, and transforming growth factor,
beta 1 pathways, whereas MLL showed enrichment to-
ward integrin, apoptosis regulators, and transcription
activators.68
These results provide more strong evidence of the
complementarity between genetic and epigenetic back-
grounds in cancer, where such interactions serve as in-
sights, in this case for understanding the onset of
AML. Identifying these subtypes in such an evident
manner could help to identify genes affected in their
expression, which could be considered targets or bio-
markers depending on their methylation status.CANCER INTEGRATED ANALYSIS BY TCGA
TCGA, along with other databases, is excellent source
of data obtained from massive genomic and epigenomic
analysis, from which almost any type of basic and clin-
ical information can be extracted on cancer. It contains
a great variety of platforms including messenger RNA,
miRNA, and DNA sequencing integrated with copy
number, methylation, and proteomic analyses. These
data respond to the need to strengthen personalized med-
icine through the study of molecular genetic and epige-
netic profiles in cancer. However, accessing the
methylation, expression, and clinical data from TCGA
database is a difficult and time-consuming task that re-
quires the help of a bioinformatics specialist. Recently,
there has been interest in offering a user-friendly inter-
face linking molecular data to clinical features—some
comparing gene expression and DNA methylation from
Gen expression Omnibus and TCGA data, such as
Wanderer,69 Methylation and Expression database of
Normal and Tumor tissues,70 or NextBio Clinical
Research platforms from Illumina.
There have recently been major publications based on
TCGA data, achieving an accurate characterization
beginning with genetic and epigenetic abnormalities.
For example, we have presented the integration between
the genomic and epigenomic data extracted from TCGA
regarding high-grade ovarian serous carcinoma and
NSCLC because these pathologies are relevant in terms
of incidence, mortality, and relapse associated with
treatment resistance. The difference in data observed
between genetic and epigenetic studies is evident, the
former being nearly 6 times greater than the latter (Fig
3). This difference will be less evident in the near future
because of improvements in the methodology and a
trend toward comprehensive studies that provide more
complete and explanatory results.
DNA methylation was achieved by 27K and 450K ar-
rays in both tumor types because of the advantages of this
technique in scalability and cost. Although the genetic
approach is heterogeneous regarding the methodology
Fig 3. Analysis in silico from TCGA data. Pie chart of the genetic and
epigenetic studies performed with NGS (RNA-seq, miRNA-seq,
DNA-seq, WES, and WGBS) and arrays (expression-exon,
expression-genes, expression-miRNA, CNV, DNA methylation
450K and 27K) in the 2 major malignancies high-grade serous carci-
noma (HGSC) and NSCLC. Data from each methodology is shown in
Supplementary Table 1. NGS, next-generation sequencing; NSCLC,
non-small cell lung cancer; miRNA, microRNA; TCGA, the cancer
genome atlas; WGBS, whole-genome bisulfite sequencing.
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miRNA-seq, DNA-seq, and Whole Exome Sequencing)
and arrays (expression-exon, expression-genes, expres-
sion-miRNA, and Copy Number Variations), probably
because of the larger number of samples analyzed (abso-
lute values for each type of cancer and methodology are
shown in Supplemental Table 1). A common genetic
feature of both tumors is the high rate of mutation in
TP53, reaching 96% in high-grade serous ovarian can-
cer71 and 46% in lung adenocarcinoma.72 This protein
is known as the guardian of the genome and is important
for stopping uncontrolled cell growth, activating DNA
repair systems, and regulating apoptosis; thus, it could
be recognized as a frequent driver mutation. This
impaired control observed in lung cancer also extends
to mutations in KRAS, mTOR, and a gene known as
SETD2, which acts as a chromatin-modifying gene.
The epigenetic analysis of lung cancer differentiated 2
methylation clusters (high and normal methylation), in
which CDKN2A was hypermethylated and its low
expression was highly related to tumors enriched for mu-
tations in SETD2.72 This situation again reveals how
important chromatin accessibility could be for normal
gene expression. SETD2 is considered a tumor suppres-
sor gene and its relationship within TP53 regulating
downstream genes has been shown73; thus, impaired
interaction among them could be indicative of tumor pro-
gression not just in lung cancer but also in other tumor
types carrying a TP53 mutation as a common feature.
Ovarian cancer exhibits a similar relationship between
mutation and hypermethylation of BRCA1. Mutationsin BRCA1/2 are detected in approximately 22% of tu-
mors, including somatic and germline mutations. Hyper-
methylation of BRCA1 was found in 11% of the tumors
analyzed in this study,71 which is lower than those previ-
ously described (24%) using MSP.74 This difference
could be because of the age of the patient cohort more
than the technologies used, given a significantly higher
hypermethylation rate of 21% has been reported in pa-
tients younger than 58 years, using the same MSP tech-
nique.75 The study performed in 2004 presents a
representative number of early stages, with almost 50%
of the patients younger than 58 years, which could
explain higher methylation rates in BRCA1. What really
matters regarding these TCGA results is the significant
association between overall survival and a defective
BRCA1. Patients with mutations in BRCA1 have a higher
survival rate than those with methylated BRCA1 and
wild-type BRCA1, thus predicting the outcome for those
patients and providing the chance of increasing survival
rates in genetic and epigenetic-BRCAness patients on a
future PARP inhibitor therapy.
ROLE OF NGS IN NONINVASIVE DNA METHYLATION
ASSESSMENT
The bodily fluids of cancer patients often harbor
increased free tumor DNA levels, which can potentially
be used for cancer detection. The epigenetic markers
can be identified in a stable and noninvasive way from
blood, saliva, urine, peritoneal fluid, and bronchoalveo-
lar fluid, which could improve the diagnosis, prognosis,
and follow-up treatment for patients. Usually, the detec-
tion of aberrant methylation is performed using MSP or
real-time MSP (qMSP), with the ability to generate
quantitatively and highly sensitive data, thus increasing
the sensitivity of 1 in 10,000 unmethylated alleles. MSP
is also more specific, because an internal probe recog-
nizes specific methylated CG positions. In fact, this
noninvasive test could be used to monitor various tu-
mors in terms of their origin. For example, the analysis
of GSTP1 in biological fluids can provide a promising
noninvasive alternative for prostate cancer diagnosis.
Three independent studies found sensitivity between
32% and 72% to identify prostate cancer by using
plasma or serum samples,76-78 with a specificity of
89% when different biological fluids were combined
(serum, urine, and ejaculate).79 In addition, MSP was
used to detect methylation in a panel of 5 genes
(BRCA1, RASFF1, APC, CDKN2A and DAPK) in 50
ovarian cancer samples, including 21 stages I/II, from
tumor tissue and matched serum and peritoneal fluid.
The findings were that 82% of the matched serum and
93% of peritoneal fluid DNA showed an identical
methylation pattern as that seen in the tumor DNA, indi-
cating that body fluids could be a good resource for
Translational Research
Volume 169 Soto et al 15analysis using this approach.74 Hypermethylation of
MGMT, a biomarker for drug response in glioblastoma
patients, can also be detected in serum with 95% sensi-
tivity and 60% specificity.80
All these studies have been performed using an
epigenetic-candidate approach with specific semiquanti-
tative or quantitative methodologies. However, more
recently, NGS has been used to determine genome-
wide profiles in serum or plasma from hepatocellular car-
cinoma,81 breast cancer,82,83 lung cancer,84 and prostate
cancer patients.85,86 Most studies indicate the need to
perform panels for specific gene candidates to expand
the coverage. Therefore, it might be possible to assess
the epigenetic state in circulating tumor DNA by NGS,
which could represent a promising tool for noninvasive
cancer detection and clinical management. However,
the existing protocols do not allow a straightforward
NGS analysis of the methylated fraction of free
circulating DNA (fcDNA), and many technical
challenges must be overcome before fcDNA studies
can reach their full potential in the epigenetic field.
There are 2 main limitations of these techniques in
plasma samples: first, fcDNA occurs at a very low
concentration and nonspecific binding dominates the
captured sample; second, the methylation enrichment
step only recovers around 7% of the total DNA
input,87,88 which reduces the amount of DNA available
for NGS library construction. Several interesting
publications have centered on optimizing the effects of
sample storage, processing and scaling of fcDNA
recovery for epigenetic purposes,89 and testing the accu-
racy of commonly used methods for the quantification of
methylated DNAmolecules, including NGS. Each meth-
odology was interrogated for the gene candidate
approach p14ARF using a panel of DNA standards com-
bined in a range of methylated and unmethylated ratios
representative of circulating free DNA levels. The study
showed that it was possible to use NGS methodology in
such samples; however, authors noted the overestimation
of the methylation content observed by NGS technol-
ogy,90 and they also reported the superior accuracy of
MethyLight quantitative PCR in comparison with the
other quantitative PCR methods tested.90 In fact, NGS
has recently been used to identify circulating DNA
methylation changes for the prediction of metastatic
breast cancer. In this study, the plasma methylome
from pools of 40 metastatic breast patients, 40 healthy
donors, and 40 disease-free survival patients was
compared usingWGBS in the Illumina HiSeq 2500 plat-
form. This analysis found genome-wide hypomethyla-
tion in plasma and focal hypermethylation on 21 CpG
islands, which were associated with metastatic breast
cancer, with a depth of coverage after the deduplication
of 7.4, 9.6, and 16.9 for each group. Because of a samplelimitation, the authors validated the methylation only in
an NGS panel of 4 genes of the 21 candidates, using
Miseq. There was a high degree of correlation between
both technologies (WGBS and MiSeq) when interro-
gating exactly 36 CpG positions, by using scatter plot
analysis and a Pearson correlation. Although this study
has the limitation of a pooling approach, it demonstrates
the potential of NGS analyzing methylation in circu-
lating DNA. Moreover, it shows an NGS cross–platform
validation that strengthens its use in plasma samples for
future diagnoses.91
Indeed, thanks to the improvement in DNA collection
using dry blood spots, the epigenetic studies using
Methyl-Cap-seq have also shown highly relevant results
without biasing the methylation profile and the quality
of data obtained from various sources.92
Improving the quality of DNA extraction from serum,
improving candidate selection to increase the
sequencing coverage, and using reference DNAmethyl-
omes all could accelerate the use of this technology in
noninvasive epigenetic tests to find suitable markers
for diagnosis and prognosis.CONCLUSIONS
NGS likely will be mandatory in a few years because
of the frantic rhythm of science, the aging population,
and the need to obtain reliable and relevant data on
various diseases, particularly cancer. The European
Commission expects that by 2025more than 20% of Eu-
ropeans will be 65 years or older, with a particularly
rapid increase in the number of those older than 80 years.
These data are closely related to the increment expected
in new cancer cases; thus, the role of these new technol-
ogies can play is crucial for the near future at both basic
and clinical levels.
The applicability of NGS technologies is on the rise,
and over time it will be more affordable for almost any
laboratory. Therefore, exposing critical topics related to
implementation of NGS is necessary.
(1) It is important to develop accuracy methodologies
regarding sample handling in terms of integrity
and acquisition of the genetic source, extraction
method, protocols, and personnel training.
(2) Other topics rely on platforms themselves as sour-
ces of variability that could interfere with repro-
ducibility, accuracy, specificity, and sensitivity.
This variability and failures generated during per-
formance of massive sequencing must be offset.
(3) The most cumbersome task of NGS is bioinfor-
matics. Massive sequencing generates hundreds
of gigabytes of data, and multiple runs could pro-
duce from terabytes to petabytes in a year, which
requires the acquisition of powerful tools for
Translational Research
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Some companies are providing cloud storage as a
solution, but that implies risks in terms of security,
particularly regarding clinical data and policies of
long-term storage.
(4) For epigenetic studies, the validation of the ob-
tained data is almost mandatory using standard
methodologies such Sanger BS, MSP, or pyrose-
quencing, primarily because of the reported bias
toward preferential DNA methylation amplifica-
tion.93
(5) Ensuring the implementation of bona fide methyl-
ation markers and improving the quality of DNA
extraction from serum might allow the future use
of NGS in a noninvasive test, which is almost
certainly the future of clinical epigenetic manage-
ment, leading to new frontiers in cancer research.ACKNOWLEDGMENTS
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